Invention Grant
US08815805B2 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment
有权
具有α5和bgr1拮抗剂用于抗血管发生和癌症治疗的制剂
- Patent Title: Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment
- Patent Title (中): 具有α5和bgr1拮抗剂用于抗血管发生和癌症治疗的制剂
-
Application No.: US13671462Application Date: 2012-11-07
-
Publication No.: US08815805B2Publication Date: 2014-08-26
- Inventor: Xiaodong Feng
- Applicant: California Northstate College of Pharmacy
- Applicant Address: US CA Rancho Cordova
- Assignee: California Northstate College of Pharmacy, LLC
- Current Assignee: California Northstate College of Pharmacy, LLC
- Current Assignee Address: US CA Rancho Cordova
- Agency: Syndicated Law, PC
- Agent Brian S. Boyer
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61P35/00 ; C07K14/515 ; C07K14/705 ; A61N5/00 ; A61K38/17 ; A61N5/10 ; A61K45/06
Abstract:
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
Public/Granted literature
- US20130225495A1 FORMULATIONS HAVING AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANGIOGENESIS AND CANCER TREATMENT Public/Granted day:2013-08-29
Information query
IPC分类:
